SCA
AYTU icon

Stonebridge Capital Advisors’s AYTU BioPharma AYTU Stock Holding History

Stonebridge Capital Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-38
Closed -$2K – 964
2021
Q3 		$2K Sell
38
-38
-50% -$2.85K ﹤0.01% 803
2021
Q2 		$10K Buy
76
+38
+100% +$4.46K ﹤0.01% 742
2021
Q1 		$6K Buy
+38
New +$6.03K ﹤0.01% 704

Other funds holding AYTU

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $102M AUM 0.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Stonebridge Capital Advisors's AYTU Position: Q4 2021 in Review

Stonebridge Capital Advisors sold out of AYTU BioPharma (AYTU) in Q4 2021, closing a stake of 38 shares — an estimated $2K sold.

Stonebridge Capital Advisors first reported a position in AYTU in Q1 2021 and held it in 3 quarters. The position peaked at $10K in Q2 2021. 37 funds tracked by Wall St. Rank hold AYTU as of Q4 2021.

  • Stonebridge Capital Advisors reported no remaining AYTU BioPharma position as of Q4 2021 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 38 AYTU BioPharma shares in Q4 2021, an estimated $2K.
  • Stonebridge Capital Advisors first reported a position in AYTU BioPharma in Q1 2021 and held it in 3 quarters.
  • Stonebridge Capital Advisors's AYTU BioPharma position peaked at $10K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q4 2021.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.